HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Don Dempsey reportedly in frame to serve as Office of Management and Budget’s leading health offical, a role that would hand him sweeping powers to rein in Kennedy’s ambitions ...

Thermo Fisher Scientific should be safe. RFK Jr. may disrupt Big Pharma, but he’s unlikely to cause research to completely ...

President Donald Trump is remaking the traditional boundaries of Washington, asserting unprecedented executive power and ...

Robert Lighthizer, the former U.S. Trade Representative, lost his bid to rejoin the White House, but he still believes the ...

Trump 2.0 prioritizes AI and space, while infectious disease and climate research decline in South Koreas context Trump 2.0s ...

Following his win over Kamala Harris, Donald Trump has been assembling the administration for his second term in the White ...

This was the environment that created Al Capone. The first celebrity gangster, Capone was happy to be perceived as the head ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

In his inaugural address, President Donald Trump promised to reform the public health system and reverse actions taken ...

Restored to power, President Trump claimed that God put him there and asserted the right to single-handedly redraw the world ...